Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-070996
Date:2021-12-02
Issuer: ITEOS THERAPEUTICS, INC. (ITOS)
Original Submission Date:

Reporting Person:

DETHEUX MICHEL
139 MAIN STREET
CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-12-20 M 9,111 a $4.30 87,311 direct
COMMON STOCK 2021-12-20 S 9,111 d $43.94 78,200 direct
COMMON STOCK 2021-12-21 M 19,226 a $4.30 97,426 direct
COMMON STOCK 2021-12-21 S 13,646 d $44.15 83,780 direct
COMMON STOCK 2021-12-21 S 5,580 d $45.06 78,200 direct
COMMON STOCK 2021-12-22 M 1,663 a $4.30 79,863 direct
COMMON STOCK 2021-12-22 S 1,514 d $44.31 78,349 direct
COMMON STOCK 2021-12-22 S 149 d $44.92 78,200 direct
COMMON STOCK 2021-12-22 S 5,007 d $44.62 73,193 direct
COMMON STOCK 2021-12-22 S 9,493 d $45.37 63,700 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 4.3 2021-12-02 deemed execution date G 313,442 (d) 2025-06-11 common stock 403,442 $4.30 90,000 direct
STOCK OPTION (RIGHT TO BUY) 4.3 2021-12-02 deemed execution date G 313,442 (a) 2025-06-11 common stock 313,442 $4.30 313,442 indirect by mg3a
STOCK OPTION (RIGHT TO BUY) 4.23 2021-12-02 deemed execution date G 185,000 (d) 2030-05-01 common stock 340,964 $4.23 155,964 direct
STOCK OPTION (RIGHT TO BUY) 4.23 2021-12-02 deemed execution date G 185,000 (a) 2030-05-01 common stock 185,000 $4.23 185,000 indirect by mg3a
STOCK OPTION (RIGHT TO BUY) 6.15 2021-12-02 deemed execution date G 52,700 (d) 2030-06-18 common stock 70,244 $6.15 17,544 direct
STOCK OPTION (RIGHT TO BUY) 6.15 2021-12-02 deemed execution date G 52,700 (a) 2030-06-18 common stock 52,700 $6.15 52,700 indirect by mg3a
STOCK OPTION (RIGHT TO BUY) 19.0 2021-12-02 deemed execution date G 776,600 (d) 2030-07-23 common stock 1,035,424 $19.00 258,824 direct
STOCK OPTION (RIGHT TO BUY) 19.0 2021-12-02 deemed execution date G 776,600 (a) 2030-07-23 common stock 776,600 $19.00 776,600 indirect by mg3a
STOCK OPTION (RIGHT TO BUY) 41.58 2021-12-02 deemed execution date G 106,200 (d) 2031-03-01 common stock 144,000 $41.58 37,800 direct
STOCK OPTION (RIGHT TO BUY) 41.58 2021-12-02 deemed execution date G 106,200 (a) 2031-03-01 common stock 106,200 $41.58 106,200 indirect by mg3a
STOCK OPTION (RIGHT TO BUY) 4.3 2021-12-20 deemed execution date M 9,111 (d) 2025-06-11 common stock 9,111 $4.30 80,889 direct
STOCK OPTION (RIGHT TO BUY) 4.3 2021-12-21 deemed execution date M 19,226 (d) 2025-06-11 common stock 19,226 $4.30 61,663 direct
STOCK OPTION (RIGHT TO BUY) 4.3 2021-12-22 deemed execution date M 1,663 (d) 2025-06-11 common stock 1,663 $4.30 60,000 direct
Footnotes
IDfootnote
f1 the transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on february 18, 2021.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f5 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f6 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f7 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. the reporting person undertakes to provide to iteos therapeutics, inc., any security holder of iteos therapeutics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
f8 the reporting person transferred these stock options to mg3a, a belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
f9 one-fourth of the shares subject to the stock option vested on january 1, 2019. thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the issuer through each applicable vesting date.
f10 one-fourth of the shares subject to the stock option vested on may 1, 2021. thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the issuer through each applicable vesting date.
f11 one-fourth of the shares subject to the stock option vested on june 1, 2021. thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the issuer through each applicable vesting date.
f12 one-fourth of the shares subject to the stock option vested on july 23, 2021. thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the issuer through each applicable vesting date.
f13 one-fourth of the shares subject to the stock option will vest on march 1, 2022, subject to the reporting person's continuous service relationship with the issuer. thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the issuer through each applicable vesting date.
WhaleWisdom Logo

Elevate your investments